Comparison of platelet fibronectin, ADP-induced platelet aggregation and serum total nitric oxide (NOx) levels in angiographically determined coronary artery disease.
BACKGROUND
Coronary thrombosis is an important determinant of prognosis in patients with acute coronary syndromes. Fibronectin is also found in platelets within the alpha secretory granules and secreted following platelet stimulation by a variety of agonist. Available data suggest that expression of platelet fibronectin on the cell surface may indicate a role in platelet aggregation and adhesion to fibrin thrombi and connective tissue. Clear evidence has emerged that a concerted action of nitric oxide (NO) generated by either endothelial or platelet NO synthases regulates platelet activation, causing inhibition of adhesion and aggregation. The aim of the present study was determining and correlating the serum total NO (NOx), platelet fibronectin and ADP-induced platelet aggregation levels in coronary artery disease (CAD) patient subgroups.


METHODS
A total of 43 coronary artery disease patients were included in this study. Peripheral blood samples from patients with coronary artery disease were obtained from the Department of Cardiology. Platelet aggregation tests with adenosine diphosphate (ADP) were analyzed by using aggregometer. Platelet fibronectin concentrations were determined by enzyme-linked immunosorbent assay (ELISA). Serum total nitric oxide (NOx) levels were determined by colorimetric method.


RESULTS
In patients with double-vessel disease, platelet fibronectin levels were found to be significantly higher than no-vessel disease (p<0.001), single-vessel disease (p<0.01) and triple-vessel disease (p<0.001). In addition, in patients with single-vessel disease platelet fibronectin levels significantly higher than no-vessel disease (p<0.05). We could not find any significant differences in ADP-induced platelet aggregation and serum NOx values between CAD patient subgroups. There was a positive correlation between platelet fibronectin levels and severity of disease (r=0.315, p<0.05).
Ekmekçi
Hakan
H
Department of Pediatric Haematology and Oncology, Bone Marrow Transplantation Unit, Istanbul Medical School, Istanbul University, Istanbul, Turkey. hakekmekci@yahoo.com
Işler
Ilknur
I
Sönmez
Hüseyin
H
Gürel
Ciğdem
C
Ciftçi
Ozlem
O
Ulutin
Turgut
T
Kökoğlu
Emine
E
Domaniç
Nergiz
N
Dirican
Ahmet
A
D000244:Adenosine Diphosphate / Q000737:chemistry*; D000368:Aged; D000792:Angiography / Q000379:methods*; D001792:Blood Platelets / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood* / Q000175:diagnosis* / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005353:Fibronectins / Q000097:blood* / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D009569:Nitric Oxide / Q000097:blood* / Q000378:metabolism; D010974:Platelet Aggregation; D011379:Prognosis; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005353:Fibronectins; D014280:Triglycerides; D009569:Nitric Oxide; D000244:Adenosine Diphosphate; D002784:Cholesterol